Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Pretreatment fasting glucose could block breast cancer progression

An increasing understanding of molecular pathways that regulate breast and colorectal cancer development and progression has produced new therapeutic agents, including the biologic agents trastuzumab, bevacizumab, and cetuximab. Identifying the indicators that are likely to predict which patients will achieve the best response to these agents represents a major challenge for contemporary oncologists.

7 Dec 2011

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

Study identifies sulfomucins as potential targets for therapies to treat chronic intestinal inflammatory disorders

In a paper published in the December 2011 issue of Experimental Biology and Medicine, a team of scientists at the University of Illinois, Urbana-Champaign led by Rex Gaskins, PhD have demonstrated that both microbial and host inflammatory factors modulate sulfomucin production in a human cell line, LS174T, that models intestinal goblet cells.

3 Dec 2011

Cancer researchers create catalog of possible targets for new treatments

As cancer researchers continue to identify genetic mutations driving different cancer subtypes, they are also creating a catalog of possible targets for new treatments.

1 Dec 2011

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Idera Pharmaceuticals, Inc. today announced that it has regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as part of an agreed-upon termination of its oncology collaboration with Merck KGaA, Darmstadt, Germany.

1 Dec 2011

Oral ingestion of apple polyphenols can prevent colitis in mice

Here's another reason why "an apple a day keeps the doctor away"-according to new research findings published in the Journal of Leukocyte Biology, oral ingestion of apple polyphenols can suppress T cell activation to prevent colitis in mice.

1 Dec 2011

Neogenix novel antibody selected as one of Windhover's 2011 Top 10 Projects to Watch

Neogenix Oncology, Inc. has announced that the company's novel antibody NEO-101, which targets pancreatic and colorectal cancer cells, has been selected as one of Windhover's 2011 Top 10 Projects to Watch.

30 Nov 2011

Elevated blood sugar levels linked with increased risk of colorectal cancer

Elevated blood sugar levels are associated with an increased risk of colorectal cancer, according to a study led by researchers at Albert Einstein College of Medicine of Yeshiva University.

30 Nov 2011

IsoRay initiates shipment of GliaSite radiation therapy system

IsoRay, Inc. announced today it has shipped its first GliaSite radiation therapy system. The Company initiated sales after receiving final approval this week from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system.

28 Nov 2011

OECD report finds U.S. pays more by far for health care

The U.S. healthcare system is more effective at delivering high costs than quality care, according to a new study that found first-rate treatment for cancer but insufficient primary care for other ailments. The study, released on Wednesday by the 34-nation Organization for Economic Cooperation and Development, or OECD, said Americans pay more than $7,900 per person for healthcare each year -- far more than any other OECD country -- but still die earlier than their peers in the industrialized world.

24 Nov 2011

IsoRay receives Washington State approval for GliaSite system to treat brain cancer

IsoRay, Inc. announced today it has received final approval from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer. In conjunction with the previously announced FDA clearance, the Washington State approval represents IsoRay's final regulatory hurdle to commence the sale of its GliaSite brain cancer treatment in the United States.

22 Nov 2011

Model NYC program aims to address growing disparities in colon cancer mortality rates

Since the 1970s, U.S. mortality rates due to colorectal cancer have declined overall, yet among blacks and Hispanics, the death rates rose. Evidence suggests that underuse of colonoscopy screening among these groups is one reason for the large disparities. In 2003, New York City launched a multifaceted campaign to improve colonoscopy rates among racial and ethnic minorities and women.

19 Nov 2011

Scientists identify novel gene mutation that causes glioblastoma

Scientists at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center, in collaboration with colleagues in Boston and South Korea, say they have identified a novel gene mutation that causes at least one form of glioblastoma (GBM), the most common type of malignant brain tumor.

18 Nov 2011

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

Genentech, a member of the Roche Group, announced today that the FDA Commissioner is revoking the approval of Avastin (bevacizumab) for the treatment of mBC in the United States.

18 Nov 2011

China Medical Technologies second quarter net revenues increase 18.1% to RMB238.5 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, announced its unaudited financial results for the second fiscal quarter ended September 30, 2011 ("2Q FY2011") today.

18 Nov 2011

Biothera completes enrollment in Imprime PGG Phase II combination study on NSCLC

EBiothera's Phase II non-small cell lung cancer (NSCLC) clinical trial evaluating Imprime PGG administered in combination with cetuximab (Erbitux), carboplatin and paclitaxel has met its goal of 90 patients and is fully enrolled, the company announced today.

17 Nov 2011

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.

16 Nov 2011

Women with inflammatory breast cancer now have a chance of treatment

Women with the deadliest and rarest form of breast cancer now have a chance of treatment where once their options were severely limited, thanks to a new discovery by George Mason University researchers.

15 Nov 2011

Fiber from whole grains reduces risk of bowel cancer: Study

The researchers from Britain and the Netherlands found that the more total dietary fiber and cereal fiber people consumed, the lower their colorectal cancer risk. For example, people who consumed an extra 90 grams of fiber from whole grains a day also had a 20 percent lower risk of colorectal cancer, according to the British Medical Journal review.

14 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011